Provectus Biopharmaceuticals Announces Presentation of Multiple Protein Kinase Signaling Targets, including WNK1, for PV-10® Immunotherapy at American Association for Cancer Research (AACR) 2022 Annual Meeting
11 avr. 2022 07h30 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 11, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose...
OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results
08 mars 2017 16h05 HE
|
OncoMed Pharmaceuticals, Inc.
Demcizumab and Tarextumab Randomized Phase 2 Data Expected 1H 2017 Anti-TIGIT IND Accepted; GITRL-Fc IND Expected 1H 2017 OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30...
OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting
05 juin 2016 09h00 HE
|
OncoMed Pharmaceuticals, Inc.
First Presentation of Combination Data for Wnt Inhibitors, Ipafricept and Vantictumab Updated Data for Demcizumab and Tarextumab Also Presented CHICAGO and REDWOOD CITY, Calif., June 05, 2016 ...